Side-by-Side Comparison
MOTS-c vs Epithalon: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how MOTS-c and Epithalon differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
MOTS-c
L2Also: Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.
Also: Epitalon, Epithalone, AEDG peptide
A tetrapeptide studied for its potential to activate telomerase and extend cellular lifespan, primarily in Russian research.
Side-by-side comparison
| Attribute | MOTS-c | Epithalon |
|---|---|---|
| Primary mechanism | Mitochondrial-Derived AMPK Activation | Telomerase Activation |
| FDA status | Research Only | Research Only |
| Evidence level | Preclinical Evidence | Preclinical Evidence |
| Human trials | None indexed | Yes (2+ indexed) |
| Studies indexed | 43 total (2 human, 22 animal) | 33 total (3 human, 18 animal) |
| Primary uses researched | Metabolic regulation, Exercise mimicry, Insulin sensitivity, Longevity | Telomerase activation, Anti-aging, Cellular longevity |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 2174.69 Da | 390.35 Da |
| Amino acids | 16 | 4 |
| Category | metabolic | longevity anti aging |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. MOTS-c acts primarily through mitochondrial-derived ampk activation, while Epithalon acts primarily through telomerase activation. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Research Only), which means the practical pathway to access is similar for each.
Evidence base. Both compounds currently sit at L2 (Preclinical Evidence) on PeptideMark's methodology.
Research focus. Published research on MOTS-c has concentrated on metabolic regulation, exercise mimicry, insulin sensitivity. Research on Epithalon has concentrated on telomerase activation, anti-aging, cellular longevity. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | MOTS-c | Epithalon |
|---|---|---|
| Documented effects | 3 total | 4 total |
| Serious events | 0 | 0 |
| Common events | 1 | 1 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
MOTS-c
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- No indexed human clinical trials
- Prohibited in competitive sport under WADA
Epithalon
Strengths
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- Few human trials — most data is preclinical
Representative studies
MOTS-c
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, et al. · Nature Communications (2021)
MOTS-c treatment improved physical performance and muscle homeostasis in aged mice, mimicking some effects of exercise.
PubMed 33420028MOTS-c peptide administration enhances mitochondrial biogenesis in skeletal muscle
Lee C, Zeng D, Dibble C, et al. · Nature Metabolism (2022)
MOTS-c 10ng/kg daily for 8 weeks increased mitochondrial DNA copy number by 2.3-fold and citrate synthase activity by 1.8-fold in skeletal muscle.
PubMed 35715704Epithalon
Peptide promotes telomere elongation in human cells
Khavinson VK, et al. · Bulletin of Experimental Biology and Medicine (2003)
Epithalon induced telomerase activity in human pulmonary fibroblasts and increased telomere length by 33%.
PubMed 14612619Epithalon (Epitalon) Increases Telomerase Activity and Extends Lifespan in Telomerase-Deficient Mice
Dilman VM, Anisimov VN. · Mechanisms of Ageing and Development (1999)
Epithalon restored telomerase activity in bone marrow and thymus; increased median lifespan by 16% and maximum lifespan by 11%.
PubMed 10614941Frequently asked
What is the main difference between MOTS-c and Epithalon?
MOTS-c is a mitochondria-derived peptide that targets the ampk pathway, studied for metabolic regulation and exercise mimicry. Its primary mechanism is mitochondrial-derived ampk activation. Epithalon is a tetrapeptide studied for its potential to activate telomerase and extend cellular lifespan, primarily in russian research. Its primary mechanism is telomerase activation. The two differ in regulatory status (Research Only vs Research Only), strength of evidence (L2 vs L2), and the primary conditions for which each is researched.
Is MOTS-c or Epithalon FDA approved?
MOTS-c: Not FDA-approved. Research compound. A mitochondria-derived peptide discovered in 2015. Epithalon: Not FDA-approved. Research compound only. Not on Category 2 list. Primarily studied in Russian research institutions.
How does the evidence base compare?
MOTS-c has 43 indexed studies (2 human, 22 animal) and is rated Preclinical Evidence. Epithalon has 33 indexed studies (3 human, 18 animal) and is rated Preclinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can MOTS-c and Epithalon be compared directly?
MOTS-c and Epithalon come from different therapeutic categories (metabolic vs longevity anti aging), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are MOTS-c and Epithalon commonly stacked together?
There is no widely documented stacking protocol combining MOTS-c and Epithalon in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, MOTS-c or Epithalon?
MOTS-c has 3 documented side effects (0 serious). Epithalon has 4 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are MOTS-c and Epithalon administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, MOTS-c or Epithalon?
"Better" depends on the therapeutic goal, regulatory context, and individual response. MOTS-c is most researched for metabolic regulation and exercise mimicry; Epithalon is most researched for telomerase activation and anti-aging. FDA status also matters: Research Only for MOTS-c vs Research Only for Epithalon. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
MOTS-c →
Full profile
Epithalon →